Left ventricular hypertrophy as a risk factor: the Framingham experience

Area of Science:

• Cardiology
• Cardiovascular Disease Research

Background:

• Left ventricular hypertrophy (LVH) is an ominous risk factor for coronary disease, stroke, and cardiac failure.
• Key determinants include elevated blood pressure, obesity, stature, and glucose intolerance, alongside cardiac valve disease and chronic heart disease (CHD).

Purpose of the Study:

• To highlight the preventable nature of LVH and its significant impact on mortality.
• To emphasize the serious risks associated with electrocardiogram-diagnosed LVH (ECG-LVH) and anatomical LVH.

Main Methods:

• The study reviews trends in LVH prevalence and its association with various risk factors and cardiovascular outcomes.
• It analyzes the prognostic implications of ECG-LVH and anatomical LVH, including mortality rates and cardiovascular event risks.

Main Results:

• Downward trends in LVH prevalence correlate with improved hypertension control, indicating preventability.
• ECG-LVH is a lethal finding associated with high mortality rates and increased risk of sudden death, ventricular ectopy, cardiac failure, stroke, and CHD.
• Both anatomical and ECG-LVH independently increase cardiovascular disease risk, with combined presence conferring a greater risk.

Conclusions:

• LVH is a potent, serious clinical finding that should be actively managed, not considered an adaptive process.
• Reversal of LVH significantly reduces all-cause, cardiovascular, and CHD mortality.
• Early detection and correction of LVH are crucial for mitigating severe cardiovascular outcomes.